Table 2. IC50 values for 5-fluorouracil, paclitaxel, and doxorubicin for wild-type and tamoxifen-resistant sublines.
| Cell line | Chemotherapeutic agents | |||||
|---|---|---|---|---|---|---|
| 5-fluorouracil | Paclitaxel | Doxorubicin | ||||
| IC50 (μM)* | RR ratio** | IC50 (μM)* | RR ratio** | IC50 (μM)* | RR ratio** | |
| wt-MCF7 | 566.7 ±164.9 | - | 2.7 ±0.3 | - | 303.3 ±68.4 | - |
| MCF7/T | 37.0 ±2.9 | 0.07 | 2.4 ±0.3 | 0.88 | 89.3 ±15.1 | 0.29 |
| wt-T47D | 1.6 ±0.2 | - | 0.9 ±0.1 | - | 30.0 ±2.1 | - |
| T47D/T | 1.3 ±0.2 | 0.81 | 1.0 ±0.1 | 1.1 | 38.8 ±2.4 | 1.29 |
| wt-BT474 | 4.3 ±1.0 | - | 3.7 ±0.2 | - | 85.3 ±10.1 | - |
| BT474/T | 5.4 ±1.0 | 1.26 | 3.3 ±0.4 | 0.89 | 73.3 ±4.7 | 0.88 |
IC50: half-maximal inhibitory concentration
* mean ± standard deviation
**Relative resistance ratio = IC50 of anticancer drug-resistant cells/IC50 of wild-type cells